Answers are grounded in this paper and cite their sources.
In vol. 109, issue 01 of the BJC , Fox et al (2013) examined the prognostic value of a range of markers of the systemic inflammatory response in patients with advanced renal cancer–in particular, whether such markers (albumin and neutrophil, lymphocyte and platelet counts or their combinations) had prognostic value in addition to an established scoring system (MSCKCC). There was an improvement in overall risk stratification (net reclassification of 26%) in patients when neutrophils, platelets and the neutrophil lymphocyte ratio were included in the scoring system. If confirmed in a similar clinical scenario, this will be a useful clinical tool to improve treatment allocation.
No takes yet. Share an insight, caveat, or question.
Donald C. McMillan (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: